Home > Browse Research > Life Sciences > Diagnostics > In Vitro Diagnostics > Companion Diagnostics

Companion Diagnostics: market research reports

Companion Diagnostics are assays intended to assist physicians in making treatment decisions. These may include tests that are being developed in conjunction, or as a companion to the drug.

They may also be tests that have been developed after a drug has come to market. The use of a diagnostic test to determine the viability of using a particular pharmaceutical product to treat a patient can be called companion diagnostics or pharmacodiagnostics.

Companion Diagnostics market research reports and industry analysis

Companion Diagnostics Partnering Terms & Agreements 4/1/2013 \| published by: Current Partnering ... understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the ... \| read more...	$2,795.00
Orphan Drugs: Market Environment Products and Companies 12/17/2012 \| published by: Espicom Healthcare Intelligence ... and high unmet medical needs. In addition, the fast track approval system allows companies to enter the market faster and more cost-effectively with the potential to extend indications. Significant unmet clinical need While orphan diseases ... \| read more...	$1,390.00
The Complete Guide to Companion Diagnostics: Market Environment Products and Companies 11/21/2012 \| published by: Espicom Healthcare Intelligence ... patients who will benefit most from, or suffer fewer side effects from targeted therapies, and thereby present a more compelling approval and prescribing case to regulators and clinicians. It could prove to be a lifesaver ... \| read more...	$1,740.00
Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes 11/9/2012 \| published by: GBI Research ... Companion Diagnostics to Optimize Therapeutic Outcomes” provides information and analysis on the major trends and issues affecting biomarkers in the drug discovery process. The report describes the history of biomarkers and their role in fulfilling ... \| read more...	$3,500.00
Companion Diagnostics and Personalized Medicine Market Report 2012 8/1/2012 \| published by: Select Biosciences Limited ... aligned in order to capture the immense potential value in targeting therapeutics to the correct patient population—the field of stratified medicine. Companion Diagnostics has been rapidly expanding over the past 3 years and in this ... \| read more...	$1,970.00
Key Findings: In Vitro Diagnostics M&A and Deal Trends 7/17/2012 \| published by: Business Insights ... treatments in the emerging companion diagnostic market. Features and benefits An overview of IVD industry trends by geography, technology type, and leading players. Analysis of partnership deal and M&A activity in the IVD market, including ... \| read more...	$1,910.00
Case Study: Personalized Cancer Therapy - Anticipated competition threatens to dampen commercial potential of new approvals 7/16/2012 \| published by: Datamonitor ... disease and patient characteristics which confer the best response rates. Identification of biomarkers and companion diagnostics will pave the way for personalized cancer therapy. Scope In-depth analysis of companion diagnostic development – when to start ... \| read more...	$1,900.00
Molecular Diagnostics: Companion Diagnostics and Personalized Medicine 5/31/2012 \| published by: Datamonitor ... so-called companion diagnostic, which typifies this movement. Features and benefits Full assessment of the market drivers and resistors for the personalized medicine movement. Detailed overview of the key pharmaceutical-diagnostic collaborative deals signed over the past ... \| read more...	$1,900.00
Companion Diagnostics - Increased Focus on Personalized Medicine and Favorable Regulatory Environment to Drive Market Growth 3/27/2012 \| published by: GlobalData ... provides information and analysis on the global companion diagnostics market. The report provides information such as current trends and developments in the global companion diagnostics market (including recent deals and industry trends). The report also ... \| read more...	$500.00
Companion Diagnostics in Personalized Medicine and Cancer Therapy 2/1/2012 \| published by: TriMark Publications ... of a drug, such as with personalized medicine for oncology patients. The molecular diagnostics field plays a vital part in personalized medicine and has greatly expanded over the past twenty years, expanding by more than ... \| read more...	$3,400.00
Companion Diagnostics Partnering Terms and Agreements 2/1/2012 \| published by: Current Partnering ... and analysis of how and why companies enter companion diagnostics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ... \| read more...	$2,695.00
Companion Diagnostics and Biomarker Development: Partnership Strategies and Benchmarks 2/1/2012 \| published by: Cutting Edge Information ... the ability to target specific patient populations — unleashing the potential for greater efficacy, accelerated regulatory approval and better reimbursement. Clarify your decision making with this report’s in-depth data benchmarks and best practices from leading ... \| read more...	$7,695.00
Companion Diagnostics 9/1/2011 \| published by: Global Industry Analysts ... period 2008 through 2017. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, bioMérieux, Clarient Inc., LabCorp, Merck & Co. Inc., Myriad Genetics, Inc., Power3 Medical Products, ... \| read more...	$4,200.00
Companion Diagnostics: World Market Outlook 2011-2021 8/22/2011 \| published by: Visiongain ... the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict ... \| read more...	$2,416.00
Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development 3/4/2011 \| published by: Datamonitor ... disease and patient characteristics which confer the best response rates. Identification of biomarkers and companion diagnostics will pave the way for personalized cancer therapy. Scope of this research In-depth analysis of companion diagnostic development - ... \| read more...	$1,900.00
In-vitro and Companion Diagnostics Industry - 2010 Yearbook 1/21/2011 \| published by: GBI Research ... report provides a market landscape, competitive landscape and market trends information on the following market categories: - clinical chemistry, immunochemistry, hematology, histology and cytology, microbiology, infectious immunology, genetic testing and companion diagnostics. The report provides ... \| read more...	$3,500.00
Companion Diagnostics: Technologies and Global Markets 11/1/2010 \| published by: BCC Research ... Valued at $170 million in 2010, analysts believe that by 2015, Oncotype Dx for breast cancer risk recurrence and drug regimen may reach $300 million, a compound annual growth rate (CAGR) of 12%. The approval ... \| read more...	$5,450.00
Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies 5/1/2010 \| published by: Arrowhead Publishers ... this paradigm promise to improve an individual’s treatment outcome and reduce healthcare expenditure, personalized medicine is set to transform the pharmaceutical/biotechnology and companion diagnostic markets. Arrowhead’s Personalized Medicine 2010 report provides an in-depth assessment of ... \| read more...	$2,495.00
U.S. Companion Diagnostics Markets 12/29/2009 \| published by: Frost & Sullivan ... key analysis and findings pertaining to the market. In addition, industry challenges and strategies for growth are in depth for the U.S. companion diagnostics market. Key developing business models in the market are also discussed. \| read more...	$6,000.00
Disruption or Advantage? Update on Companion Diagnostics 9/15/2009 \| published by: Decision Resources ... diagnostics can be used to predict drug response and treatment effi cacy- therefore, companion diagnostics are also the perfect means to fulfi llment of the promise of personalized medicine. But the advantages of companion diagnostics ... \| read more...	$4,600.00
Testing Services Markets, SNP Analysis, DNA Sequencing, Retail Clinics, Companion Diagnostics 8/1/2008 \| published by: Kalorama Information ... the important areas that will have a transforming impact on the diagnostic industry: Companies are now performing diagnostic tests as a service rather than simply selling kit to laboratories. Are companies seeking profit, or a ... \| read more...	$2,995.00
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends 6/5/2008 \| published by: Decision Resources ... drug because of their particular metabolic activity. The concept of companion diagnostics as an integral component of personalized medicine-RxDx-is an emerging and critical paradigm for drug development and use. What is driving that paradigm? Get ... \| read more...	$1,125.00
Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in 'Theranostics' and Personalized Medicine) 6/1/2008 \| published by: Kalorama Information ... the co-development of testing products to enhance the value and efficacy of a therapeutic, companion diagnostics is widely seen as an important growth strategy in both the diagnostic and pharmaceutical industries. It is envisioned as ... \| read more...	$2,995.00
Monoclonal Therapeutics and Companion Diagnostic Products 1/1/2008 \| published by: BCC Research ... We were particularly interested in the position of the antibody market in the immediate future compared to how it has performed in the recent past as well as how the market compares to that of ... \| read more...	$5,450.00
Companion Diagnostics: Enabling Personalized Medicines in Cancer 10/26/2006 \| published by: Decision Resources ... critical biomarkers, however, they also need to consider technology options, potential diagnostics partners, and regulatory hurdles. Get the Answers You Need to Shape Your Strategy Companion diagnostics are becoming an integral part of the design ... \| read more...	$4,600.00